Extended Data Table 2 Breakdown and description of grade 3 and 4 toxicities, assigned as ‘unlikely related or unrelated to study medication’ medication, by IT nivolumab dose level and individual patient

From: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results